Annual report pursuant to Section 13 and 15(d)

11. Stockholders' Equity (Details Narrative)

v3.7.0.1
11. Stockholders' Equity (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Reverse stock split On May 16, 2016, our board of directors approved a reduction, on a 1 for 33 basis  
IPR&D expense $ 34,902,444  
Prepaid expense 1,224,009 $ 247,298
Warrants modification expense 1,121,466 933,195
Research and development expense $ 43,737,814 3,434,016
Common Stock [Member]    
Conversion of stock, shares issued 118,500  
Series B Preferred Stock [Member]    
Conversion of stock, shares converted 118,500  
Serum [Member]    
Stock issued for research and development, shares 211,486  
Stock issued for research and development, value $ 750,000  
Stock issued for settlement of prior purchases, amount 163,000  
Serum [Member] | Warrants [Member]    
Incremental value expense of warrants $ 204,000  
Warrants issued 212,122  
Research and development expense $ 1,370,000  
Serum [Member] | Serum Institute 2014 Warrant and Serum Institute Partner Warrants [Member]    
Warrants modification expense $ 1,121,466 $ 706,500
SynBio LLC [Member] | Common Stock [Member]    
Conversion of stock, shares converted 970,000  
SynBio LLC [Member] | Series A Preferred Stock [Member]    
Conversion of stock, shares issued 970,000  
Asset Purchase Agreement [Member] | Dr. Genkin [Member]    
Stock issued with APA, shares issued   330,000
Asset Purchase Agreement [Member] | Mr. Surkhov [Member]    
Stock issued with APA, shares issued   330,000
Asset Purchase Agreement [Member] | Pharmsynthez [Member]    
Shares issued in connection with asset purchase, shares issued 3,050,000  
IPR&D expense $ 39,500,000  
Prepaid expense 3,740,000  
Public Offering [Member]    
Proceeds from issuance of stock, net 8,970,000  
Payment of stock issuance fees 530,000  
Beneficial conversion feature fully accreted $ 4,035,260